<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04000919</url>
  </required_header>
  <id_info>
    <org_study_id>18.1268</org_study_id>
    <nct_id>NCT04000919</nct_id>
  </id_info>
  <brief_title>Effects of 5HTP and LDOPA on CNS Excitability After SCI</brief_title>
  <official_title>The Effects of 5-hydroxytryptophan (5-HTP) and L-3,4-dihydroxyphenylalanine (L-DOPA) Supplementation on Central Nervous System Excitability and Motor Function in Individuals With Spinal Cord Injury</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jessica M D'Amico</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Louisville</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will examine whether supplementation with the serotonin and dopamine precursors,
      5HTP and L-DOPA can alter central nervous system excitability and improve motor function
      after incomplete and complete spinal cord injuries.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 19, 2019</start_date>
  <completion_date type="Anticipated">December 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2023</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
    <masking_description>Both the participant and assessors are blinded to which drug/placebo the participant reviews because all drugs are housed in similar capsules. Only the PI and caregiver will be aware of which drug will be administered for safety purposes.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change in corticospinal excitability</measure>
    <time_frame>Pre drug-intake, 30minutes, 60minutes, 90minutes, 120minutes and 150minutes post drug-intake</time_frame>
    <description>Transcranial magnetic stimulation motor-evoked potentials</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in motoneuron excitability</measure>
    <time_frame>Pre drug-intake, 30minutes, 60minutes, 90minutes, 120minutes and 150minutes post drug-intake</time_frame>
    <description>F waves</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in spinal excitability</measure>
    <time_frame>Pre drug-intake, 30minutes, 60minutes, 90minutes, 120minutes and 150minutes post drug-intake</time_frame>
    <description>H reflex</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in spasticity</measure>
    <time_frame>Pre drug-intake, 30minutes, 60minutes, 90minutes, 120minutes and 150minutes post drug-intake</time_frame>
    <description>Cutaneomuscular reflex</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum and Urine Analysis of serotonin and dopamine</measure>
    <time_frame>150minutes post drug-intake</time_frame>
    <description>5-HIAA (serum), 5-HTP (serum and whole blood), catecholamines and homovanillic acid (urine)</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Spinal Cord Injuries</condition>
  <arm_group>
    <arm_group_label>Effects of single-dose of carbidopa (50mg) on CNS excitability</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Participants will visit the lab and on one of four different occasions they will receive carbidopa only (50 mg). Neurophysiology outcome measures will be obtained at 30, 60, 90, 120 and 150 min post drug-intake.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Effects of single-dose placebo on CNS Excitability</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will visit the lab and on one of four different occasions and will receive a placebo. Neurophysiology outcome measures will be obtained at 30, 60, 90, 120 and 150 min post drug-intake.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Effects of single-dose 5HTP/carbidopa on CNS Excitability</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>During one of the four occasions participants visit the lab they will receive 5HTP combined with carbidopa (50-200mg HTP/50mg carbidopa). Neurophysiology outcome measures will be obtained at 30, 60, 90, 120 and 150 min post drug-intake.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Effects of single-dose L-DOPA/carbidopa on CNS Excitability</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>During one of the four occasions participants visit the lab they will receive L-DOPA combined with carbidopa (50-200mg L-DOPA/50mg carbidopa). Neurophysiology outcome measures will be obtained at 30, 60, 90, 120 and 150 min post drug-intake.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5HTP</intervention_name>
    <description>5HTP/carbidopa (50-200 mg 5-HTP/50 mg carbidopa)</description>
    <arm_group_label>Effects of single-dose 5HTP/carbidopa on CNS Excitability</arm_group_label>
    <other_name>carbidopa</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>L-DOPA</intervention_name>
    <description>L-DOPA/carbidopa (50-200 mg L-DOPA/50 mg carbidopa)</description>
    <arm_group_label>Effects of single-dose L-DOPA/carbidopa on CNS Excitability</arm_group_label>
    <other_name>Sinemet</other_name>
    <other_name>Carbidopa</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo oral tablet</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Effects of single-dose placebo on CNS Excitability</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carbidopa</intervention_name>
    <description>Carbidopa (50mg)</description>
    <arm_group_label>Effects of single-dose of carbidopa (50mg) on CNS excitability</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Individuals aged 18-65 years of age.

          -  Patients must have suffered a trauma to the spinal cord at least 1 year ago or longer.

          -  Patients must exhibit some degree of spasticity which can be self-reported (Penn spasm
             frequency) or if assessed by a physiotherapist, a modified Ashworth spasticity score
             greater than 1

        Exclusion Criteria:

          -  Individuals with damage to the nervous system other than to the spinal cord

          -  Pregnant or breastfeeding women

          -  Alcoholic patients

          -  Patients with a history of seizures or epilepsy

          -  Patients with a history of suicidal thoughts or behaviors

          -  Patients with active or inactive implants including cardiac pacemakers, implantable
             defibrillators, ocular implants, deep brain stimulators, vagus nerve stimulator, and
             implanted medication pumps

          -  Patients with conductive, ferromagnetic or other magnetic-sensitive metals implanted
             in their head

          -  Patients with:

          -  Known or suspected allergy to the medication or the ingredients

          -  Cardiovascular disease including history of heart attack or heart rhythm
             irregularities

          -  Coronary artery disease

          -  Comatose or depressed states due to CNS depressants

          -  Endocrine dysfunction

          -  Blood dyscrasias

          -  Bone marrow depression

          -  History of seizures

          -  Hypocalcemia

          -  History of stomach ulcers

          -  Wide-angle glaucoma

          -  Phenylketonuria

        Patients taking:

          -  Monoamine oxidase inhibitor therapy

          -  Serotonergic antidepressants: selective serotonin and norepinephrine reuptake
             inhibitors

          -  Tricyclic antidepressants

          -  Any type of serotonergic agonist

          -  Dopamine D2 receptor antagonists

          -  Amphetamine

          -  CNS depressants

          -  Levodopa

          -  Lithium

          -  Anti-hypertensive drugs (Carbidopa and L-DOPA)

          -  Iron salts

          -  Metoclopramide

          -  Phenothiazine medication
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jessica D'Amico, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Louisville</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jessica D'Amico, PhD</last_name>
    <phone>15025827443</phone>
    <email>jessica.damico@louisville.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Louisville, Kentucky Spinal Cord Injury Research Centre</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jessica D'Amico, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Jessica D'Amico, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>David Rouffet, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>June 19, 2019</study_first_submitted>
  <study_first_submitted_qc>June 25, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 27, 2019</study_first_posted>
  <last_update_submitted>June 27, 2019</last_update_submitted>
  <last_update_submitted_qc>June 27, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 1, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Louisville</investigator_affiliation>
    <investigator_full_name>Jessica M D'Amico</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Spinal Cord Injuries</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carbidopa</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

